TY - JOUR
T1 - The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging
T2 - Comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model
AU - Runge, Val M.
AU - Biswas, Jonmenjoy
AU - Wintersperger, Bernd J.
AU - Baumann, Shannon S.
AU - Jackson, Carney B.
AU - Herborn, Christoph U.
AU - Patel, Tushar
PY - 2006/3
Y1 - 2006/3
N2 - OBJECTIVES: The objectives of this study were to analyze the differences in contrast enhancement using gadobenate dimeglumine (Gd-BOPTA or MultiHance) at 3 T versus 1.5 T and to compare Gd-BOPTA with a standard gadolinium chelate, gadopentetate dimeglumine (Gd-DTPA or Magnevist), at 3 T in a rat glioma model. MATERIALS AND METHODS: Twelve rats with surgically implanted gliomas were randomized to either comparing Gd-BOPTA at 1.5 T versus 3 T (n = 7) or comparing Gd-BOPTA and Gd-DTPA at 3 T (n = 5). Matched T1-weighted spin-echo techniques were used for both comparisons and the order of examinations was randomized. Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and lesion enhancement (LE) were evaluated using a region-of-interest analysis. A veterinary histopathologist evaluated all brain specimens. RESULTS: In the evaluation of Gd-BOPTA at 3 T and 1.5 T, there were significant increases in SNR, LE, and CNR at 3 T. Average increases in brain and tumor SNR were 93% (P < 0.0001) and 92% (P < 0.0001), respectively. CNR increased by 121% (P < 0.0001). Comparison of Gd-BOPTA and Gd-DTPA at 3 T demonstrated significantly higher CNR and LE with Gd-BOPTA. CNR increased by 35% (P = 0.002). LE increased by 44% (P = 0.03). CONCLUSIONS: Gd-BOPTA provides significantly higher CNR at 3 T compared with 1.5 T and also demonstrates significantly higher CNR when compared with a standard Gd-chelate at 3 T. As a result of transient protein binding, Gd-BOPTA may be superior to standard gadolinium chelates in neurologic imaging at 3 T.
AB - OBJECTIVES: The objectives of this study were to analyze the differences in contrast enhancement using gadobenate dimeglumine (Gd-BOPTA or MultiHance) at 3 T versus 1.5 T and to compare Gd-BOPTA with a standard gadolinium chelate, gadopentetate dimeglumine (Gd-DTPA or Magnevist), at 3 T in a rat glioma model. MATERIALS AND METHODS: Twelve rats with surgically implanted gliomas were randomized to either comparing Gd-BOPTA at 1.5 T versus 3 T (n = 7) or comparing Gd-BOPTA and Gd-DTPA at 3 T (n = 5). Matched T1-weighted spin-echo techniques were used for both comparisons and the order of examinations was randomized. Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and lesion enhancement (LE) were evaluated using a region-of-interest analysis. A veterinary histopathologist evaluated all brain specimens. RESULTS: In the evaluation of Gd-BOPTA at 3 T and 1.5 T, there were significant increases in SNR, LE, and CNR at 3 T. Average increases in brain and tumor SNR were 93% (P < 0.0001) and 92% (P < 0.0001), respectively. CNR increased by 121% (P < 0.0001). Comparison of Gd-BOPTA and Gd-DTPA at 3 T demonstrated significantly higher CNR and LE with Gd-BOPTA. CNR increased by 35% (P = 0.002). LE increased by 44% (P = 0.03). CONCLUSIONS: Gd-BOPTA provides significantly higher CNR at 3 T compared with 1.5 T and also demonstrates significantly higher CNR when compared with a standard Gd-chelate at 3 T. As a result of transient protein binding, Gd-BOPTA may be superior to standard gadolinium chelates in neurologic imaging at 3 T.
KW - Brain neoplasms
KW - Contrast enhancement
KW - Gadobenate dimeglumine
KW - Gadolinium chelates
KW - Magnetic resonance
UR - http://www.scopus.com/inward/record.url?scp=33745893815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745893815&partnerID=8YFLogxK
U2 - 10.1097/01.rli.0000191332.24773.e7
DO - 10.1097/01.rli.0000191332.24773.e7
M3 - Article
C2 - 16481906
AN - SCOPUS:33745893815
SN - 0020-9996
VL - 41
SP - 244
EP - 248
JO - Investigative Radiology
JF - Investigative Radiology
IS - 3
ER -